A Changing Paradigm: Defining the Future Role of SGLT-2 Inhibitors

Published: 02 September 2021

  • Views:

    Views Icon 2667
  • Likes:

    Heart Icon 3

Overview

Full programme

  • Views:

    Views Icon 2667
  • Likes:

    Heart Icon 3

Overview

SGLT-2 inhibitors represent one of the single biggest advances in heart failure practice, but how confident are you when comes to using them in different patients, and what can we reasonably expect in the coming months and years from ongoing trials? 
 

Watch our esteemed faculty – Prof Andrew Coats, Dr Biykem Bozkurt and Prof Carolyn Lam as they summarise the latest SGLT-2 inhibitor data in heart failure and attempt to demystify some important practical points around their use with other agents.
 

To conclude the session, the panel will consider best practices in light of the evidence and guidance we have available today and how to implement this in practice.
 

ESC Congress 2021

Supported by the Boehringer Ingelheim & Lilly Alliance

Key Learning Objectives

  • Review recent data from randomised controlled trials and meta-analyses on the use of SGLT-2 inhibitors for HFrEF and HFpEF
  • Describe parallel and sequential approaches to HFrEF management
  • Recall best practice recommendations using SGLT-2 inhibitors in patients with HFrEF without type-2 diabetes
  • Apply appropriate treatment algorithms to the management of HF patients

Target Audience

  • Heart Failure Specialists
  • General Cardiologists
  • General Practitioners

Series overview

Part 1

SGLT-2 inhibitors in heart failure: Where are we now and where are we heading?

1 session

  • SGLT-2 inhibitors in heart failure: Where are we now and where are we heading?

    Watch now

Part 2

Best practice of SGLT2 inhibitors in HFrEF: A Practical Overview

1 session

  • Best practice of SGLT2 inhibitors in HFrEF: A Practical Overview

    Watch now

Part 3

Q&A

1 session

Faculty biographies